PMID- 38520423
OWN - NLM
STAT- Publisher
LR  - 20240323
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
DP  - 2024 Mar 18
TI  - Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea.
LID - S0091-6749(24)00129-5 [pii]
LID - 10.1016/j.jaci.2024.01.025 [doi]
AB  - BACKGROUND: There is growing evidence that the coronavirus disease 2019 
      (COVID-19) vaccination can affect the regulation of the immune system, leading to 
      the development of autoimmune diseases. However, the autoimmune adverse events 
      (AEs) after COVID-19 vaccination remain largely unclear. OBJECTIVE: We sought to 
      investigate the autoimmune AEs after COVID-19 vaccination from a population-based 
      cohort in South Korea. METHODS: A total of 4,203,887 participants, representing 
      50% of the population residing in Seoul, were recruited from the National Health 
      Insurance Service database and then divided into 2 groups on the basis of 
      COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs 
      of autoimmune AEs were assessed following COVID-19 vaccination. RESULTS: The 
      incidence of vitiligo has been observed to be significantly higher in the 
      vaccination group compared with the no vaccination group. The cumulative 
      incidence of vitiligo began to show a significant difference starting 2 weeks 
      after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the 
      no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 
      95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the 
      risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 
      2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or 
      mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813). CONCLUSIONS: Vitiligo as an 
      autoimmune AE was noted to be substantially higher in the COVID-19-vaccinated 
      group compared with the controls. Therefore, the occurrence of vitiligo could be 
      considered as one of the significant AEs post-COVID-19 vaccination.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Kim, Hong Jin
AU  - Kim HJ
AD  - Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College 
      of Medicine, Inje University, Seoul, Korea.
FAU - Kim, Min-Ho
AU  - Kim MH
AD  - Informatization Department, Ewha Womans University Seoul Hospital, Ewha Womans 
      University, Seoul, Korea.
FAU - Park, Seong Jun
AU  - Park SJ
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
FAU - Choi, Myeong Geun
AU  - Choi MG
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
FAU - Chun, Eun Mi
AU  - Chun EM
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, School of Medicine, Ewha Womans University, Seoul, Korea. Electronic 
      address: cem@ewha.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20240318
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
SB  - IM
OTO - NOTNLM
OT  - COVID-19
OT  - autoimmune adverse events
OT  - complications
OT  - vaccination
OT  - vitiligo
EDAT- 2024/03/23 20:47
MHDA- 2024/03/23 20:47
CRDT- 2024/03/23 11:38
PHST- 2023/09/11 00:00 [received]
PHST- 2024/01/22 00:00 [revised]
PHST- 2024/01/26 00:00 [accepted]
PHST- 2024/03/23 20:47 [medline]
PHST- 2024/03/23 20:47 [pubmed]
PHST- 2024/03/23 11:38 [entrez]
AID - S0091-6749(24)00129-5 [pii]
AID - 10.1016/j.jaci.2024.01.025 [doi]
PST - aheadofprint
SO  - J Allergy Clin Immunol. 2024 Mar 18:S0091-6749(24)00129-5. doi: 
      10.1016/j.jaci.2024.01.025.